Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanciu, Ioana-Miruna, Pirlog, Cristina Florina, Anghel, Andrei-Wilhelm, Parosanu, Andreea Ioana, Olaru, Cristina Mihaela, Orlov-Slavu, Cristina, Iaciu, Ion Cristian, Popa, Ana Maria, Vrabie, Radu Constantin, Nitipir, Cornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145154/
https://www.ncbi.nlm.nih.gov/pubmed/37109654
http://dx.doi.org/10.3390/medicina59040696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145154/
https://www.ncbi.nlm.nih.gov/pubmed/37109654
http://dx.doi.org/10.3390/medicina59040696

Ejemplares similares